TLR7 agonist 22

TLR7 agonist 22 (Compound 11a) emerges as a selective TLR7 agonist with an IC50 value of 25.86 μM. TLR7 agonist 22 inhibits the cellular HBsAg secretion and effectively activates TLR7, thereby inducing the secretion of TLR7-regulated cytokines IL-12, TNF-αand IFN-αin human PBMC cells. TLR7 agonist 22 is a promising for research in the field of developing novel immunomodulatory anti-HBV agents[1].

Product Specifications

CAS Number

[3036114-68-5]

UNSPSC

12352005

Target

Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tlr7-agonist-22.html

Smiles

FC1=C(OCC2=NC(CC(N3CCC4=C3C=CC=C4)=O)=CS2)C=CC=C1

Molecular Formula

C20H17FN2O2S

Molecular Weight

368.42

References & Citations

[1]Li S, et al. Exploration of 1- (indolin-1-yl) -2- (thiazol-2-yl) ethan-1-one derivatives as novel anti-HBV agent with potential TLR7 agonist 22onistic effect. Eur J Med Chem. 2024 Jun 8;275:116575.